Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on a patented platform technology that can provide up to 12 times productivity and thereby up to 80% cost reduction compared to standard systems in development of biological drugs

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (Xcimzane ™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Approved and pending patent applications


Biosimilars under development

Capital Markets Day 17 May, 2021

At Xbrane Biopharma

Press Releases

16 May 2021

Xbrane announces ambition to generate positive operating cash flow monthly by late 2023/early 2024 and to initiate one new biosimilar development program per annum.

11 May 2021

Xbrane is hosting a Virtual Capital Markets Day on May 17th, 2021

06 May 2021

Announcement from Xbrane Biopharma’s annual general meeting

06 May 2021

Xbrane Biopharma releases interim report for January – March 2021

04 May 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – March, 2021 on May 6, 2021.

15 Apr 2021

Xbrane Biopharma expands in-house Biosimilar development capabilities with new Biotech lab and invites participants to Virtual Capital Markets day on May 17.

31 Mar 2021

Xbrane Biopharma releases Annual report for 2020

30 Mar 2021

Notice of annual general meeting in Xbrane Biopharma AB

15 Mar 2021

Xbrane strengthens the organization with the appointment of Erik Domines as General Counsel